{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:05:05Z","timestamp":1784027105826,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.06.007","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:41:20Z","timestamp":1753299680000},"page":"93-128","source":"Crossref","is-referenced-by-count":1,"title":["The peptidomimetic approach for the design of viral protease inhibitors"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.enz.2025.06.007_bib0001","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/bs.enz.2025.06.007_bib0002","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/anie.199312441","article-title":"Peptidomimetics for receptor ligands\u2014discovery, development, and medical perspectives","volume":"32","author":"Giannis","year":"1993","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"10.1016\/bs.enz.2025.06.007_bib0003","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/anie.199416991","article-title":"Peptidomimetics\u2014Tailored Enzyme inhibitors","volume":"33","author":"Gante","year":"1994","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"10.1016\/bs.enz.2025.06.007_bib0004","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1039\/D0CS00102C","article-title":"Peptidomimetic toolbox for drug discovery","volume":"49","author":"Lenci","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/bs.enz.2025.06.007_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1367-5931(98)80119-1","article-title":"Peptidomimetic design","volume":"2","author":"Ripka","year":"1998","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0006","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ddr.21406","article-title":"Limiting assumptions in the design of peptidomimetics","volume":"78","author":"Marshall","year":"2017","journal-title":"Drug Dev. Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0007","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1002\/anie.201412070","article-title":"Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes","volume":"54","author":"Pelay-Gimeno","year":"2015","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"10.1016\/bs.enz.2025.06.007_bib0008","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/ar900020x","article-title":"The beta-D-glucose scaffold as a beta-turn mimetic","volume":"42","author":"Hirschmann","year":"2009","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0009","series-title":"Drug Design","first-page":"119","volume":"X","author":"Farmer","year":"1980"},{"key":"10.1016\/bs.enz.2025.06.007_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/anie.201205674","article-title":"N-methylation of peptides and proteins: an important element for modulating biological functions","volume":"52","author":"Chatterjee","year":"2013","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"10.1016\/bs.enz.2025.06.007_bib0011","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/ar8000603","article-title":"N-methylation of peptides: a new perspective in medicinal chemistry","volume":"41","author":"Chatterjee","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0012","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/cr040669e","article-title":"Proteases universally recognize beta strands in their active sites","volume":"105","author":"Tyndall","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/bs.enz.2025.06.007_bib0013","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/17460441.2016.1245720","article-title":"Discovery and optimization of peptide macrocycles","volume":"11","author":"White","year":"2016","journal-title":"Expert Opin. Drug Discov"},{"key":"10.1016\/bs.enz.2025.06.007_bib0014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1073\/pnas.70.3.684","article-title":"Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone","volume":"70","author":"Burgus","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2025.06.007_bib0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nchem.1062","article-title":"Contemporary strategies for peptide macrocyclization","volume":"3","author":"White","year":"2011","journal-title":"Nat. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0016","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/bip.360310619","article-title":"Backbone cyclization: a new method for conferring conformational constraint on peptides","volume":"31","author":"Gilon","year":"1991","journal-title":"Biopolymers"},{"key":"10.1016\/bs.enz.2025.06.007_bib0017","doi-asserted-by":"crossref","first-page":"9606","DOI":"10.1021\/ja961626l","article-title":"Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides","volume":"118","author":"Miller","year":"1996","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/bs.enz.2025.06.007_bib0018","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/1568026618666180518095755","article-title":"Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)-mediated macrocyclization of peptides: impact on conformation and biological activity","volume":"18","author":"Testa","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.007_bib0019","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","article-title":"Proteases: history, discovery, and roles in health and disease","volume":"294","author":"Bond","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.enz.2025.06.007_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1039\/b208248a","article-title":"HIV-1 protease: mechanism and drug discovery","volume":"1","author":"Brik","year":"2003","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bmc.2010.11.042","article-title":"Investigation of \u03b1-phenylnorstatine and \u03b1-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors","volume":"19","author":"W\u00e5ngsell","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0023","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/jm00014a001","article-title":"Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections","volume":"38","author":"De Clercq","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0024","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1021\/jm100233b","article-title":"Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents","volume":"53","author":"Gupta","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0025","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1021\/jo030063a","article-title":"Solid-phase synthesis of HTLV-1 protease inhibitors containing hydroxyethylamine dipeptide isostere","volume":"68","author":"Akaji","year":"2003","journal-title":"J. Org. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0026","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bmcl.2007.01.028","article-title":"Novel hydroxamic acid-related phosphinates: inhibition of neutral aminopeptidase N (APN)","volume":"17","author":"Drag","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.007_bib0027","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1021\/jm701555p","article-title":"Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV","volume":"51","author":"Nakatani","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0028","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bmc.2009.12.051","article-title":"Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1\u2032 alkoxy residues and an aminoethylene (AE) central core","volume":"18","author":"Bj\u00f6rklund","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0029","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med. Chem"},{"key":"10.1016\/bs.enz.2025.06.007_bib0030","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.3390\/ijms24087226","article-title":"Investigation of the compatibility between warheads and peptidomimetic sequences of protease inhibitors-a comprehensive reactivity and selectivity study","volume":"24","author":"M\u00fcller","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.enz.2025.06.007_bib0031","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bmc.2019.04.002","article-title":"Characterising covalent warhead reactivity","volume":"27","author":"Martin","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211002621","article-title":"A review: mechanism of action of antiviral drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0033","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0034","doi-asserted-by":"crossref","first-page":"31257","DOI":"10.1074\/jbc.M502577200","article-title":"Mechanism of the maturation process of SARS-CoV 3CL protease","volume":"280","author":"Hsu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"Borges","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.007_bib0036","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.2183354","article-title":"Rational design of peptide-based HIV proteinase inhibitors","volume":"248","author":"Roberts","year":"1990","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.007_bib0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.007_bib0038","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/ar700109k","article-title":"Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection","volume":"41","author":"Njoroge","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0039","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1021\/acs.jmedchem.4c02561","article-title":"Discovery of Nirmatrelvir (PF-07321332): a potent, orally active inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) main protease","volume":"68","author":"Tuttle","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bip.10231","article-title":"Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations","volume":"66","author":"Rich","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/bs.enz.2025.06.007_bib0041","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm990412m","article-title":"Protease inhibitors: current status and future prospects","volume":"43","author":"Leung","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0042","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1073\/pnas.91.9.4096","article-title":"L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor","volume":"91","author":"Vacca","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2025.06.007_bib0043","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/092986707782360141","article-title":"Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors","volume":"14","author":"Mastrolorenzo","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0044","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0045","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic peptides as drug candidates: recent progress and remaining challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/bs.enz.2025.06.007_bib0046","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi\u00ae","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.007_bib0047","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1139\/cjm-2020-0572","article-title":"Dengue virus: epidemiology, biology, and disease aetiology","volume":"67","author":"Roy","year":"2021","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0048","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1021\/acs.jmedchem.5b01653","article-title":"The medicinal chemistry of dengue virus","volume":"59","author":"Behnam","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0049","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.enz.2025.06.007_bib0050","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.bbrc.2005.03.107","article-title":"Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites","volume":"330","author":"Chanprapaph","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.enz.2025.06.007_bib0051","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2011.07.002","article-title":"Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease","volume":"92","author":"Sch\u00fcller","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0052","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/JVI.06225-11","article-title":"Ligand-bound structures of the dengue virus protease reveal the active conformation","volume":"86","author":"Noble","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0053","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aag2419","article-title":"Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor","volume":"353","author":"Lei","year":"2016","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.007_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2018.10.006","article-title":"Structures of Zika virus NS2B-NS3 protease in complex with peptidomimetic inhibitors","volume":"160","author":"Phoo","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.enz.2025.06.007_bib0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jobm.202000537","article-title":"SARS-CoV-2, the pandemic coronavirus: molecular and structural insights","volume":"61","author":"Kadam","year":"2021","journal-title":"J. Basic Microbiol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0057","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.007_bib0058","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.007_bib0059","doi-asserted-by":"crossref","unstructured":"WHO, Coronavirus disease (COVID-19) pandemic, accessed 10 May 2025 https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019","DOI":"10.46945\/bpj.10.1.03.01"},{"key":"10.1016\/bs.enz.2025.06.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: Challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.007_bib0061","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0062","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.007_bib0063","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.007_bib0064","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/bs.enz.2025.06.007_bib0065","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0066","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1021\/acs.oprd.2c00375","article-title":"Early clinical development of lufotrelvir as a potential therapy for COVID-19","volume":"27","author":"Allais","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/bs.enz.2025.06.007_bib0067","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.enz.2025.06.007_bib0068","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1021\/acs.jmedchem.4c02561","article-title":"Discovery of Nirmatrelvir (PF-07321332): a potent, orally active inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) main protease","volume":"68","author":"Tuttle","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0069","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.007_bib0070","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.enz.2025.06.007_bib0071","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.enz.2025.06.007_bib0072","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.007_bib0073","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","article-title":"Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-chymotrypsin-like protease of SARS-CoV-2","volume":"15","author":"Grifagni","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.007_bib0074","doi-asserted-by":"crossref","first-page":"27248","DOI":"10.1021\/jacs.3c12678","article-title":"A chemical strategy for the degradation of the main protease of SARS-CoV-2 in cells","volume":"145","author":"Sang","year":"2023","journal-title":"J. Am. Chem. Soc."}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:53:38Z","timestamp":1768938818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":74,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.06.007","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}